Please assess the completion status of the following clinical trial:

Trial Title: Danazol for Genetic Bone Marrow and Lung Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Short age-adjusted telomere length in the first percentile and/or a mutation in telomerase genes~ 2. One or more of the following cytopenia(s).~* Anemia~  1. Symptomatic anemia with a hemoglobin \< 9.5 g/dL or red cell transfusion requirements \> 2 units/month for at least 2 months~ 2. Reticulocyte count \< 60,000 /microL~* Thrombocytopenia~  1. Platelet count \< 30,000 /microL or \< 50,000 /microL associated with bleeding~ 2. Decreased megakaryocytic precursors in the bone marrow~* Neutropenia~  1. Absolute neutrophil count \< 1,000 /microL~     OR~     3. Idiopathic pulmonary fibrosis diagnosed by either a lung biopsy of high resolution computed tomography scan of the chest according to guidelines from the American Thoracic Society and European Respiratory Society~     4. Age greater than or equal to 2 years~     5. Weight \> 12 kg~     EXCLUSION CRITERIA:~    1. Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient s ability to tolerate protocol therapy, or that death within 30 days is likely~    2. Potential subjects with cancer who are on active chemotherapeutic treatment~    3. Current pregnancy, or unwillingness to avoid pregnancy if of childbearing potential~    4. Not able to understand the investigational nature of the study or give informed consent or does not have a legally authorized representative or surrogate that can provide informed consent.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Danazol (Type: EXPERIMENTAL): Single arm in which danazol is administered orally at 800 mg daily for 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).